AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer
Phase 2
Withdrawn
- Conditions
- Metastatic Colorectal Cancer
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT00233623
- Locations
- 🇮🇹
Research Center, Bari, Italy
🇮🇹Research Site, Venezia, Italy
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
Phase 3
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT00233610
- Locations
- 🇮🇹
Research Site, Roma, Italy
DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines
Completed
- Conditions
- Diabetes Mellitus Type 2Crestor, RosuvastatinLDL CholesterolObservational
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2500
- Registration Number
- NCT00233649
- Locations
- 🇳🇱
Research Site, Zwolle, Netherlands
Pulmicort Asthma Prevention (Post-PAC)
Not Applicable
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2008-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00233584
- Locations
- 🇩🇰
Research Site, Copenhagen, Denmark
Efficacy Study of the Effect of Budesonide on Emphysema
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT00232674
- Locations
- 🇩🇰
Research Site, Gentofte, Denmark
Long Term Safety & Efficacy of Budesonide Inhalation Suspension in Japanese Children With Bronchial Asthma
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00232648
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
Phase 3
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-10-05
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 452
- Registration Number
- NCT00232661
- Locations
- 🇳🇱
Research Site, Sittard, Netherlands
Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects
Phase 4
Completed
- Conditions
- Healthy
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00230516
- Locations
- 🇺🇸
Research Site, Oklahoma City, Oklahoma, United States
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 317
- Registration Number
- NCT00229697
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
Phase 2
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00229684
- Locations
- 🇺🇸
Research Site, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath